Targeting the catecholamine-cytokine axis to prevent SARS-CoV-2 cytokine storm syndrome

Maximilian F. Konig[1,2], Mike Powell[3], Verena Staedtke[4], Ren-Yuan Bai[5], David L. Thomas[6], Nicole Fischer[7], Sakibul Huq[5], Adham M. Khalafallah[5], Allison Koenecke[8], Nickolas Papadopoulos[1], Kenneth W. Kinzler[1], Bert Vogelstein[1], Joshua T. Vogelstein[3*], Susan Athey[9*], Shibin Zhou[1*], Chetan Bettegowda[1,5*]

[1]Ludwig Center, Lustgarten Laboratory, and the Howard Hughes Medical Institute at The Johns Hopkins Kimmel Cancer Center, Baltimore, MD, USA

[2]Division of Rheumatology, The Johns Hopkins University School of Medicine, Baltimore, MD, USA

[3]Department of Biomedical Engineering, Institute of Computational Medicine, The Johns Hopkins University, Baltimore, MD, USA

[4]Department of Neurology, The Johns Hopkins University School of Medicine, Baltimore, MD, USA

[5]Department of Neurosurgery, The Johns Hopkins University School of Medicine, Baltimore, MD, USA

[6]Division of Infectious Diseases, The Johns Hopkins University School of Medicine, Baltimore, MD, USA

[7]The Johns Hopkins University School of Medicine, Baltimore, MD, USA

[8]Institute for Computational & Mathematical Engineering, Stanford University, Stanford, CA, USA

[9]Stanford Graduate School of Business, Stanford University, Stanford, CA, USA

*To whom correspondence should be addressed.

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) encompasses a phylogenetically defined group of evolving viral strains that have caused an ongoing pandemic. Coronavirus disease 2019 (COVID-19) refers to the clinical syndrome of SARS-CoV-2 infection which disproportionally affects older adults with underlying hypertension and heart disease[1]. The mortality of severe COVID-19 appears

to be driven by acute respiratory distress syndrome (ARDS) and a dysregulated immune response to SARS-CoV-2[2–4].

Emerging evidence suggests that a subset of COVID-19 is characterized by the development of a cytokine storm syndrome (CSS) that resembles cytokine release syndrome (CRS) in chimeric antigen receptor (CAR)-T cell therapy[2,4,5]. Hyper-inflammation in COVID-19 is associated with elevation of pro-inflammatory cytokines including interleukin (IL)-6, IL-2R, IL-8, tumor necrosis factor-α, and granulocyte-colony stimulating factor[4,6]. This is similar to the exuberant cytokine production by lung-infiltrating monocytes/macrophages and pneumocytes observed in SARS-CoV and MERS-CoV infection[7].

Targeting the hyper-inflammation in COVID-19 may be critical for reducing mortality. IL-6 levels diverge profoundly between non-survivors and survivors in the third week after symptom onset and are predictors of COVID-19 severity and in-hospital mortality[1,8,9]. Tocilizumab, a monoclonal antibody targeting the IL-6 receptor, is currently being investigated for the treatment of patients with COVID-19-CSS (ChiCTR2000029765, NCT04306705, NCT04310228)[10–12]. Pending data from randomized controlled trials, retrospective data from 21 patients with severe or critical COVID-19 treated with tocilizumab suggests that inhibition of the IL-6 signaling axis is highly effective[13]. However, given the cost, immunosuppression, and potential adverse reactions of tocilizumab, this strategy will likely be restricted to select patients in developed countries.

We have recently shown that CRS observed with bacterial infections, CAR-T cells, and other T cell-activating therapies is accompanied by a surge in catecholamines[14]. Catecholamines enhance inflammatory injury by augmenting the production of IL-6 and other cytokines through a self-amplifying feed-forward loop in immune cells that requires alpha-1 adrenergic receptor (α1-AR) signaling[14]. Prophylactic inhibition of catecholamine synthesis with metyrosine, a tyrosine hydroxylase antagonist, reduced levels of catecholamines and cytokine responses and resulted in markedly increased survival following various inflammatory stimuli in mice. Similar protection against a hyper-inflammatory stimulus was observed with prazosin, demonstrating that α1-AR antagonists can also prevent cytokine storm[14].

To date, no controlled trials have examined the benefits of α1-AR antagonism for the prevention of CSS and ARDS in human subjects. To investigate a potential role for α1-AR antagonists in preventing poor outcomes in ARDS, we conducted a retrospective analysis of hospitalized patients diagnosed with ARDS. Using data from the Truven Health MarketScan Research Database (2010-2017), we identified 12,673 men (age 45-64) with "ARDS" as identified using International Classification of Diseases (ICD)-9 and ICD-10 diagnosis codes. Of these, 1,189 patients (9.4%) were prescribed α1-AR antagonists in the previous year, 8.1% died in the hospital, and 15.6% received invasive mechanical ventilation. Logistic regression models were used to estimate adjusted odds ratios (AOR) and confidence intervals (CI) correlating receipt of α1-AR antagonists (doxazosin, prazosin, silodosin, terazosin, and tamsulosin) in the previous year with these outcomes. Models were adjusted for comorbid conditions in the prior year as well as age and year of hospital admission.

We found that patients with prior use of α1-AR antagonists had lower adjusted odds of the composite of invasive mechanical ventilation and mortality compared to non-users (AOR 0.80, 95% CI 0.69-0.94, p=0.008) (Figure 1). The unadjusted association was similar in magnitude (OR 0.80, 95% CI 0.68-0.94, p=0.007), as were results analyzing each component endpoint separately. Mirroring findings from pre-clinical models, these findings support a clinical rationale to study α1-AR antagonists in the prophylaxis of ARDS and states of local and systemic immune dysregulation. Given the limitations of claims databases and retrospective analyses, our data on their own cannot establish causality or a therapeutic benefit of α1-AR antagonists.

The findings discussed herein offer a rationale for studying α1-AR antagonists in the prophylaxis of COVID-19-CSS. However, all drugs can have unanticipated side effects, and the incompletely understood relationship between hypertension and COVID-19 suggests caution in using any agent that impacts blood pressure[15]. Prospective, double-blinded clinical trials of α1-AR antagonists in high-risk patients, when administered prior to symptom onset, will therefore be required to assess their utility in preventing COVID-19-CSS. Prazosin is inexpensive and safe, as has been documented by long-term

treatment of millions of patients with benign prostatic hyperplasia, hypertension, and other conditions. We emphasize that the extensive experience with using prazosin for other indications should prioritize - *not obviate* - rigorous, controlled clinical research rather than indiscriminate off-label use in patients exposed to SARS-CoV-2. Such trials could be expeditiously implemented in areas suffering from high infection rates that threaten to overwhelm hospital capacity. We encourage readers to recommend specific populations and trial designs to test the hypothesis proposed herein.



Figure 1. Logistic regression of the composite of invasive mechanical ventilation and in-hospital mortality in patients with ARDS who are on α1-AR antagonists using data from MarketScan Research Database. *adjusted for comorbid hypertension, ischemic heart disease, acute myocardial infarction, heart failure, chronic obstructive pulmonary disease, diabetes mellitus, benign prostatic hyperplasia, and post-traumatic stress disorder identified from health care encounters in the prior year as well as age and year.

Acknowledgements: We thank Adam Sacarny (Columbia University) for advice in processing and analyzing health care claims data. Dr. Sacarny was not compensated for his assistance. This study used the MarketScan Research Databases.

References:

1 Zhou F, Yu T, Du R, *et al.* Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. *The Lancet* 2020; : S0140673620305663.

2 Ruan Q, Yang K, Wang W, Jiang L, Song J. Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China. *Intensive Care Med* 2020; published online March 3. DOI:10.1007/s00134-020-05991-x.

3 Qin C, Zhou L, Hu Z, *et al.* Dysregulation of immune response in patients with COVID-19 in Wuhan, China. *Clinical Infectious Diseases* 2020; : ciaa248.

4 Huang C, Wang Y, Li X, *et al.* Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. *The Lancet* 2020; **395**: 497–506.

5 Mehta P, McAuley DF, Brown M, Sanchez E, Tattersall RS, Manson JJ. COVID-19: consider cytokine storm syndromes and immunosuppression. *The Lancet* 2020; published online March 13. DOI:https://doi.org/10.1016/S0140-6736(20)30628-0.

6 Chen G, Wu D, Guo W, *et al.* Clinical and immunologic features in severe and moderate forms of Coronavirus Disease 2019. *medRxiv* 2020; : 2020.02.16.20023903.

7 Channappanavar R, Perlman S. Pathogenic human coronavirus infections: causes and consequences of cytokine storm and immunopathology. *Semin Immunopathol* 2017; **39**: 529–39.

8 Chen X, Zhao B, Qu Y, *et al.* Detectable serum SARS-CoV-2 viral load (RNAaemia) is closely associated with drastically elevated interleukin 6 (IL-6) level in critically ill COVID-19 patients. *medRxiv* 2020; : 2020.02.29.20029520.

9 Liu T, Zhang J, Yang Y, *et al.* The Potential Role of IL-6 in Monitoring Coronavirus Disease 2019. Rochester, NY: Social Science Research Network, 2020 https://papers.ssrn.com/abstract=3548761 (accessed March 17, 2020).

10 Chinese Clinical Trial Register (ChiCTR) - The world health organization international clinical trials registered organization registered platform. http://www.chictr.org.cn/showprojen.aspx?proj=49409 (accessed March 16, 2020).

11 Tocilizumab vs CRRT in Management of Cytokine Release Syndrome (CRS) in COVID-19 - Full Text View - ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT04306705 (accessed March 16, 2020).

12 Favipiravir Combined With Tocilizumab in the Treatment of Corona Virus Disease 2019 - Full Text View - ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT04310228 (accessed March 17, 2020).

13 Xu X, Han M, Li T, *et al.* Effective Treatment of Severe COVID-19 Patients with Tocilizumab. *ChinaXiv* 2020; published online March 5. DOI:ChinaXiv:202003.00026.

14 Staedtke V, Bai R-Y, Kim K, *et al.* Disruption of a self-amplifying catecholamine loop reduces cytokine release syndrome. *Nature* 2018; **564**: 273–7.

15 Zheng Y-Y, Ma Y-T, Zhang J-Y, Xie X. COVID-19 and the cardiovascular system. *Nature Reviews Cardiology* 2020; published online March 5. DOI:10.1038/s41569-020-0360-5.

COI: In 2017, Johns Hopkins University filed a patent application on the use of various drugs to prevent cytokine release syndromes, on which V.S., R.B., B.V., K.W.K., and S.Z. are listed as inventors.